Status:

RECRUITING

Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma

Lead Sponsor:

Costantino Errani

Conditions:

Bone Metastases

Eligibility:

All Genders

18+ years

Brief Summary

From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological ima...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases
  • Availability of imaging and clinical data
  • Availability of at least one follow-up during the last 12 months form diagnosis

Exclusion

  • At least one inclusion creteria not met

Key Trial Info

Start Date :

September 23 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT06524843

Start Date

September 23 2024

End Date

December 1 2026

Last Update

December 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS Istituto Ortopedico Rizzoli

Bologna, Emilia-Romagna, Italy, 40134

Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma | DecenTrialz